Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Arcus Biosciences (RCUS)

Arcus Biosciences Q1 revenue falls to $17 million; net loss widens to $128 million

Negative Impact 3 of 5 earnings Written later

Arcus Biosciences reported first-quarter 2026 results, with revenue of $17 million, down from $28 million a year earlier, and a net loss of $128 million, up from $112 million. Net loss per share was $1.02, compared with $1.14, on a higher share count of 125.4 million versus 98.4 million. Cash, cash equivalents and marketable securities fell to $876 million, and the company expects to end 2026 with about $600 million.

Key points

  • Revenue was $17 million for Q1 2026, versus $28 million in Q1 2025, mainly from lower development services revenue from the Gilead collaboration.
  • Net loss was $128 million, versus $112 million; basic and diluted loss per share was $1.02, versus $1.14.
  • Cash, cash equivalents and marketable securities were $876 million at March 31, 2026, versus $1.0 billion at December 31, 2025.
  • Arcus expects full-year 2026 GAAP revenue of $50 million to $65 million and cash runway until at least the second half of 2028.

The filing

CompanyArcus Biosciences (RCUS)
Form8-K, current report
Filed with the SECMay 5, 2026, 4:09 PM ET
Accession number0001724521-26-000032

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:49 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.